NYSEAMERICAN:CVM CEL-SCI - CVM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. $2.68 -0.02 (-0.74%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.63▼$2.7350-Day Range$2.29▼$5.2352-Week Range$1.88▼$6.51Volume37,979 shsAverage Volume107,882 shsMarket Capitalization$117.06 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CEL-SCI MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside497.0% Upside$16.00 Price TargetShort InterestBearish11.70% of Shares Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.79) to $0.28 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCEL-SCI has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, CEL-SCI has a forecasted upside of 497.0% from its current price of $2.68.Amount of Analyst CoverageCEL-SCI has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.70% of the outstanding shares of CEL-SCI have been sold short.Short Interest Ratio / Days to CoverCEL-SCI has a short interest ratio ("days to cover") of 28.5, which indicates bearish sentiment.Change versus previous monthShort interest in CEL-SCI has recently increased by 0.79%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCEL-SCI does not currently pay a dividend.Dividend GrowthCEL-SCI does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCEL-SCI has received a 61.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CEL-SCI is -0.84. Previous Next 0.7 News and Social Media Coverage News SentimentCEL-SCI has a news sentiment score of -0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for CVM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CEL-SCI insiders have not sold or bought any company stock.Percentage Held by Insiders15.89% of the stock of CEL-SCI is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.75% of the stock of CEL-SCI is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CEL-SCI are expected to grow in the coming year, from ($0.79) to $0.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CEL-SCI is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CEL-SCI is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCEL-SCI has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CEL-SCI (NYSEAMERICAN:CVM) StockCEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.Read More Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter. Email Address CVM Stock News HeadlinesJanuary 22, 2023 | thestreet.comCEL-SCI Stock Gaps Down On Today's Open (CVM)January 3, 2023 | finance.yahoo.comCVM: A New Year AheadFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.October 19, 2022 | finance.yahoo.comGlobal Orphan Drugs Market to Reach $545.4 Billion by 2027 - Yahoo FinanceOctober 18, 2022 | nasdaq.comPre-market Movers: AVEO, RMED, GRNA, ARC, INPX… - NasdaqOctober 18, 2022 | globenewswire.comGlobal Orphan Drugs Market to Reach $545.4 Billion by 2027 - GlobeNewswireOctober 18, 2022 | rttnews.comPre-market Movers: AVEO, RMED, GRNA, ARC, INPX… - RTTNewsOctober 17, 2022 | businesswire.comCEL-SCI'S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment - Business WireFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.October 10, 2022 | finance.yahoo.comHead and Neck Cancer Clinical Trial Pipeline: Analysis of 130+ Key Companies Working in the Domain | DelveInsight - Yahoo FinanceSeptember 30, 2022 | seekingalpha.comCEL-SCI's (CVM) Multikine - Potential Game-Changing Cancer Drug On The Horizon - Seeking AlphaSeptember 27, 2022 | finance.yahoo.comHead and Neck Cancer Market to Surge at a CAGR of 5.1% by 2032 | DelveInsight - Yahoo FinanceSeptember 27, 2022 | bloomberg.comHead and Neck Cancer Market to Surge at a CAGR of 5.1% by 2032 | DelveInsight - BloombergSeptember 12, 2022 | businesswire.comCEL-SCI'S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer - Business WireSeptember 12, 2022 | seekingalpha.comCEL-SCI says neoadjuvant multikine shows response in head/neck cancer in trial - Seeking AlphaSeptember 12, 2022 | finance.yahoo.comCEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck CancerSeptember 9, 2022 | seekingalpha.comCEL-SCI to soon address FDA concerns on cancer therapySeptember 8, 2022 | proactiveinvestors.comCEL-SCI Corp letter to shareholders details positive results from Phase 3 study of Multikine - Proactive Investors USASeptember 7, 2022 | benzinga.comCEL-SCI (CVM) – Cel-Sci Corporation Issues Letter to Shareholders; Multikine Reduced And Eliminated Tumor - BenzingaAugust 29, 2022 | benzinga.comCVM: ClinicalTrials Submission - BenzingaAugust 24, 2022 | finance.yahoo.comPeloton to sell some fitness equipment on Amazon - Yahoo FinanceAugust 24, 2022 | finance.yahoo.comCVM: ClinicalTrials SubmissionAugust 19, 2022 | finance.yahoo.comCEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov - Yahoo FinanceAugust 19, 2022 | businesswire.comCEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov - Business WireAugust 19, 2022 | streetinsider.comCEL-SCI Corp (CVM) Announces Phase 3 Multikine Head and Neck Cancer Results Posted on Clinicaltrials.gov - StreetInsider.comAugust 16, 2022 | nz.finance.yahoo.comCEL-SCI Corporation (CVM)August 15, 2022 | seekingalpha.comCel-Sci GAAP EPS of -$0.66 (NYSE:CVM) - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter. Email Address CVM Company Calendar Last Earnings12/28/2022Today2/03/2023Next Earnings (Estimated)2/13/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:CVM CUSIPN/A CIK725363 Webwww.cel-sci.com Phone(703) 506-9460Fax703-506-9471Employees2,020Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$16.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+497.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.64% Return on Assets-55.12% Debt Debt-to-Equity Ratio0.31 Current Ratio7.71 Quick Ratio7.17 Sales & Book Value Annual Sales$560,000.00 Price / Sales209.04 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book2.05Miscellaneous Outstanding Shares43,680,000Free Float36,443,000Market Cap$117.06 million OptionableOptionable Beta1.68 Key ExecutivesGeert R. KerstenCEO, Chief Financial Officer, Treasurer & DirectorPatricia B. PrichepSecretary & Senior Vice President-OperationsEyal TalorChief Scientific OfficerWilliam JonesVice President-Quality AssuranceDaniel H. ZimmermanSenior VP-Research & Cellular ImmunologyKey CompetitorsInstil BioNASDAQ:TILGenenta ScienceNASDAQ:GNTAGamida CellNASDAQ:GMDABlack Diamond TherapeuticsNASDAQ:BDTXBig Cypress AcquisitionOTCMKTS:BCYPView All CompetitorsInsiders & InstitutionsD.A. Davidson & CO.Sold 87,410 shares on 2/3/2023Ownership: 0.874%Cutter & CO Brokerage Inc.Bought 11,945 shares on 2/3/2023Ownership: 0.195%Simplex Trading LLCSold 13,500 shares on 2/2/2023Ownership: 0.000%Threadgill Financial LLCBought 16,170 shares on 1/31/2023Ownership: 0.037%Ingalls & Snyder LLCSold 38,305 shares on 1/31/2023Ownership: 0.027%View All Institutional Transactions CVM Stock - Frequently Asked Questions Should I buy or sell CEL-SCI stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CEL-SCI in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CVM shares. View CVM analyst ratings or view top-rated stocks. What is CEL-SCI's stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month price objectives for CEL-SCI's shares. Their CVM share price forecasts range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 497.0% from the stock's current price. View analysts price targets for CVM or view top-rated stocks among Wall Street analysts. Are investors shorting CEL-SCI? CEL-SCI saw a drop in short interest in December. As of December 30th, there was short interest totaling 5,070,000 shares, a drop of 8.8% from the December 15th total of 5,560,000 shares. Based on an average daily trading volume, of 181,500 shares, the short-interest ratio is presently 27.9 days. View CEL-SCI's Short Interest. When is CEL-SCI's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023. View our CVM earnings forecast. How were CEL-SCI's earnings last quarter? CEL-SCI Co. (NYSEAMERICAN:CVM) posted its earnings results on Wednesday, December, 28th. The company reported ($0.21) EPS for the quarter. When did CEL-SCI's stock split? Shares of CEL-SCI reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of CEL-SCI own? Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Savara (SVRA), Molecular Templates (MTEM), Gilead Sciences (GILD), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA), VBI Vaccines (VBIV) and CymaBay Therapeutics (CBAY). What is CEL-SCI's stock symbol? CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM." Who are CEL-SCI's major shareholders? CEL-SCI's stock is owned by many different institutional and retail investors. Top institutional shareholders include D.A. Davidson & CO. (0.87%), Cutter & CO Brokerage Inc. (0.20%), Threadgill Financial LLC (0.04%), Threadgill Financial LLC (0.04%), Simplex Trading LLC (0.00%) and Ingalls & Snyder LLC (0.03%). Insiders that own company stock include Bruno Jean-Marie Baillavoine, Eyal Talor, Geert R Kersten, John Cipriano, Patricia B Prichep, Peter R Young and Robert Eugene Watson. View institutional ownership trends. How do I buy shares of CEL-SCI? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CEL-SCI's stock price today? One share of CVM stock can currently be purchased for approximately $2.68. How much money does CEL-SCI make? CEL-SCI (NYSEAMERICAN:CVM) has a market capitalization of $117.06 million and generates $560,000.00 in revenue each year. The company earns $-36,360,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. How many employees does CEL-SCI have? The company employs 2,020 workers across the globe. How can I contact CEL-SCI? CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The official website for the company is www.cel-sci.com. The company can be reached via phone at (703) 506-9460, via email at gdewindt@cel-sci.com, or via fax at 703-506-9471. This page (NYSEAMERICAN:CVM) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.